Walmart stock cratered 9.2% on August 20 after comparable sales growth missed Wall Street estimates sharply, knocking 703 points off the dow industrials average and splitting analyst opinion.
- WMT fell 9.2% to $103.84 on August 20, its steepest single-session decline since May 2022, when the stock shed 11%.
- U.S. comparable sales rose just 2.6% in Q2 2027, well below the 3.5%-3.7% Wall Street forecast, the slowest pace since Q4 2020.
- JPMorgan upgraded WMT to Overweight and set a $125 price target, while Oppenheimer downgraded to Perform citing pharmacy headwinds and valuation risk.
Lead
Walmart (WMT) suffered its worst trading session in four years on August 20, 2026, plunging 9.2% to close at $103.84 after second-quarter results revealed a pronounced slowdown in U.S. same-store sales growth. The selloff dragged the dow industrials average down 703 points, or 1.32%, to 52,759 - making WMT, which carries a heavy weighting in the 30-stock blue-chip gauge, the single largest drag on the index for the session. The Dow Jones U.S. Retail Index fell an additional 2.5% in sympathy.What Caused WMT Stock to Drop 9%?
The selloff was not triggered by an earnings miss. Walmart reported adjusted earnings per share of $0.81 and revenue of $187.94 billion for the fiscal second quarter, both ahead of consensus. The culprit was the pace of domestic growth. U.S. comparable sales expanded just 2.6% year over year - the slowest reading since the fourth quarter of 2020 and a sharp shortfall against analyst forecasts of 3.5% to 3.7%. Management attributed a significant portion of the deceleration to lower drug prices stemming from Medicare price negotiation legislation, which compressed the health and wellness category. Stripping out that drag, core merchandise comparable growth ran at 3.4%.
The guidance reset amplified the damage. Walmart guided third-quarter adjusted EPS to a range of $0.62-$0.64, versus the $0.68 Wall Street had modeled, and full-year adjusted EPS to $2.80-$2.87, below FactSet consensus despite representing a nominal raise to prior company guidance.
Why Did JPMorgan Call the Selloff a Buying Opportunity?
JPMorgan upgraded WMT to Overweight from Neutral in the wake of the decline, setting a new price target of $125 - a 21% premium to the August 20 close, though down from the bank's prior target of $137. Analyst Christopher Horvers argued the selloff represented a "washout," with bear-case concerns now priced in, and pointed to the acceleration of alternative profit pools - advertising, membership, and marketplace - alongside AI-driven automation benefits as underappreciated drivers. The bank views Walmart as structurally positioned to gain share during any consumer slowdown in the second half of 2026.
Not all major firms concurred. Oppenheimer downgraded WMT to Perform from Outperform and withdrew its prior $140 price target, citing pharmacy-related revenue headwinds, elevated valuation that it considered susceptible to a further de-rating, and Street forecasts already modeled well ahead of the company's own longer-term targets.
Market Reaction and Retail Sector Fallout
The severity of Walmart's move reverberated across the consumer discretionary and staples sectors. The retailer's weighting in the dow industrials average ensured the index absorbed a disproportionate share of the damage even as broader equity markets registered only moderate losses. Treasury yields spiked during the session, compounding pressure on rate-sensitive equities and limiting any offsetting gains elsewhere.
Walmart separately announced a 5% dividend increase and disclosed plans to pass tariff-related cost savings to consumers through price reductions - moves that management characterized as evidence of competitive positioning but that the market treated as secondary to the guidance shortfall.
Outlook
Walmart's August 20 session marks a pivotal recalibration. The stock enters the remainder of 2026 with a compressed valuation, a reset earnings base, and split analyst conviction. Bulls rest their case on structural growth in high-margin alternative revenue streams, AI-driven cost efficiency, and eventual stabilization in health-and-wellness comparable sales once Medicare pricing headwinds anniversary. Bears point to the risk that consumer trade-down behavior plateaus and that consensus forecasts remain too aggressive relative to company guidance. The divergence between JPMorgan's upgrade and Oppenheimer's downgrade reflects genuinely uncertain near-term visibility, with the next comparable sales reading the clearest near-term test of which thesis proves correct.
Mentioned tickers: WMT, JPM




